Yardley V - Search Results

1

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.

Thompson AM, O'Connor PD, Marshall AJ, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Franzblau SG, Wan B, Wang Y, Ma Z, Cooper CB, Denny WA. Thompson AM, et al. Among authors: yardley v. J Med Chem. 2017 May 25;60(10):4212-4233. doi: 10.1021/acs.jmedchem.7b00034. Epub 2017 May 11. J Med Chem. 2017. PMID: 28459575 Free PMC article.

2

Chemotherapy of leishmaniasis.

Croft SL, Yardley V. Croft SL, et al. Among authors: yardley v. Curr Pharm Des. 2002;8(4):319-42. doi: 10.2174/1381612023396258. Curr Pharm Des. 2002. PMID: 11860369 Review.

3

Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis.

Nan A, Croft SL, Yardley V, Ghandehari H. Nan A, et al. Among authors: yardley v. J Control Release. 2004 Jan 8;94(1):115-27. doi: 10.1016/j.jconrel.2003.09.012. J Control Release. 2004. PMID: 14684276

4

Antituberculotic and antiprotozoal activities of primin, a natural benzoquinone: in vitro and in vivo studies.

Tasdemir D, Brun R, Yardley V, Franzblau SG, Rüedi P. Tasdemir D, et al. Among authors: yardley v. Chem Biodivers. 2006 Nov;3(11):1230-7. doi: 10.1002/cbdv.200690124. Chem Biodivers. 2006. PMID: 17193236

5

Synthesis and in vitro protozoocidal activity of diazabicyclic benzotropolone derivatives.

Khrizman A, Moulthrop JS, Little S, Wharton H, Yardley V, Moyna G. Khrizman A, et al. Among authors: yardley v. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4183-6. doi: 10.1016/j.bmcl.2007.05.044. Epub 2007 May 18. Bioorg Med Chem Lett. 2007. PMID: 17532634

6

Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation.

Decuypere S, Vanaerschot M, Rijal S, Yardley V, Maes L, de Doncker S, Chappuis F, Dujardin JC. Decuypere S, et al. Among authors: yardley v. Parasitology. 2008 Feb;135(2):183-94. doi: 10.1017/S0031182007003782. Epub 2007 Oct 12. Parasitology. 2008. PMID: 17931458

7

Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).

Yang M, Arai C, Bakar Md A, Lu J, Ge JF, Pudhom K, Takasu K, Kasai K, Kaiser M, Brun R, Yardley V, Itoh I, Ihara M. Yang M, et al. Among authors: yardley v. J Med Chem. 2010 Jan 14;53(1):368-73. doi: 10.1021/jm9013086. J Med Chem. 2010. PMID: 19894726

8

Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.

Wenzel NI, Chavain N, Wang Y, Friebolin W, Maes L, Pradines B, Lanzer M, Yardley V, Brun R, Herold-Mende C, Biot C, Tóth K, Davioud-Charvet E. Wenzel NI, et al. Among authors: yardley v. J Med Chem. 2010 Apr 22;53(8):3214-26. doi: 10.1021/jm9018383. J Med Chem. 2010. PMID: 20329733

9

Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.

Fortin A, Hendrickx S, Yardley V, Cos P, Jansen H, Maes L. Fortin A, et al. Among authors: yardley v. J Antimicrob Chemother. 2012 Nov;67(11):2707-12. doi: 10.1093/jac/dks273. Epub 2012 Jul 10. J Antimicrob Chemother. 2012. PMID: 22782488

10

Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.

Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, Martin D, Puri SK. Gupta S, et al. Among authors: yardley v. J Antimicrob Chemother. 2015 Feb;70(2):518-27. doi: 10.1093/jac/dku422. Epub 2014 Nov 10. J Antimicrob Chemother. 2015. PMID: 25389223

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters